文献速递外周动脉疾病

深静脉经导管动脉化与常规治疗在无选择慢性肢体威胁性缺血患者中的临床与经济结局比较

Clinical and economic outcomes of transcatheter arterialization of the deep veins in no-option chronic limb-threatening ischemia patients compared with conventional therapy.
PubMed 文献 · J Vasc Surg · 2026-01-27

基于PROMISE I和II试验的TADV患者与CLariTI注册的倾向匹配SoC患者比较,1年肢体挽救率74.6% vs 57.8%、生存率86.4% vs 71.1%、无截肢生存率64.9% vs 39.1%均显著更优。Markov模型显示TADV增加1.15 QALY、增加成本24,738美元,增量成本效果比为21,600美元/QALY,具有成本效果。

要点

  • TADV较SoC显著改善无选择CLTI患者1年肢体挽救、生存和无截肢生存。
  • TADV增量成本效果比为21,600美元/QALY,在敏感性分析中均具成本效果。
  • 研究排除基线透析患者,结果外推需谨慎。

核心结论

  • TADV使用LimFlow系统较SoC显著改善1年肢体挽救、生存和无截肢生存率。
  • 基于健康经济模型,TADV在终身视野下具有成本效果,可证明其前期费用的合理性。

研究设计与样本

  • PROMISE I和II为单臂、多中心、前瞻性研究,评估TADV在无选择CLTI患者中的安全性和有效性。
  • SoC来自同期CLariTI自然史注册,采用倾向评分匹配,匹配变量包括年龄、性别、糖尿病状态和Rutherford分级。
  • 对118例TADV患者和132例SoC患者进行倾向评分匹配,排除基线透析患者,最终分析228例(114对匹配)。
  • 采用Cox回归和Kaplan-Meier方法分析1年临床结局,采用决策分析Markov模型评估终身成本效果。

主要发现

  • 1年肢体挽救率TADV组74.6% vs SoC组57.8%(P = .003)。
  • 1年生存率TADV组86.4% vs SoC组71.1%(P = .013)。
  • 1年无截肢生存率TADV组64.9% vs SoC组39.1%(P < .001)。
  • 终身视野下TADV较SoC增加1.15 QALY(2.32 vs 1.17),增加成本24,738美元(101,235 vs 76,497),预计生存获益2.33生命年。
  • 基础案例增量成本效果比为21,600美元/QALY。

关键数值与推荐

  • PROMISE和CLariTI队列均包括Rutherford 5级或6级患者。
  • 匹配后分析228例患者(114对匹配)。
  • 1年肢体挽救率74.6% vs 57.8%(P = .003)。
  • 1年生存率86.4% vs 71.1%(P = .013)。
  • 1年无截肢生存率64.9% vs 39.1%(P < .001)。

临床怎么用

  • 对于无选择CLTI患者,TADV可考虑作为改善肢体挽救和生存的治疗选择。
  • TADV的增量成本效果比在可接受范围内,支持其作为具有成本效果的干预措施。
  • 基线透析患者被排除,临床决策时需考虑该人群证据不足。

局限性

  • PROMISE I和II为单臂研究,SoC为倾向匹配的非随机注册队列,存在残余混杂可能。
  • 分析排除了基线透析患者,结果不适用于该人群。
  • 成本效果基于模型预测和假设,需实际数据验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Transcatheter arterialization of the deep veins (TADV) has been demonstrated to be safe and effective among no-option chronic limb-threatening ischemia (CLTI) patients, who lack suitable treatment alternatives. This study reports clinical and economic outcomes based on pooled data from PROMISE I and II trials of TADV for no-option compared with propensity-matched standard of care (SoC) patients from the concurrent CLariTI natural history registry. METHODS: PROMISE I and II were single-arm, multicenter, prospective studies evaluating the safety and efficacy of TADV in no-option CLTI patients, assessed by an independent committee. Both the PROMISE and CLariTI cohorts included patients with Rutherford disease class 5 or 6. Propensity score matching (PSM) was performed on 118 TADV patients and 132 SoC patients based on age, sex, diabetes status, and Rutherford classification. Patients on dialysis at baseline were excluded from analysis. One-year clinical outcomes including limb salvage, overall survival, and amputation-free survival (AFS), were analyzed using Cox regression and Kaplan-Meier methods. The cost effectiveness of TADV vs SoC was evaluated using a decision analytic Markov model, projecting outcomes over a lifetime horizon. One-year clinical event rates previously discussed were relied upon in conjunction with contemporary US cost data, including the incorporation of the new technology add-on payment granted for TADV. The resulting incremental cost-effectiveness ratio, reported in dollars per quality-adjusted life-year (QALY) gained, was evaluated against established willingness-to-pay thresholds. Extensive scenario and sensitivity analyses were performed. RESULTS: After matching, 228 patients (114 matched pairs) were analyzed. At 1 year, compared with matched SoC, patients treated with TADV demonstrated superior limb salvage rates (74.6% vs 57.8%; P = .003), survival rates (86.4% vs 71.1%; P = .013), and AFS rates (64.9% vs 39.1%; P < .001). Over lifetime and under the base case assumptions, TADV (vs SoC) provided an additional 1.15 QALYs (2.32 vs 1.17), with increased costs of $24,738 ($101,235 vs $76,497), and a projected survival gain of 2.33 life-years. The base case incremental cost-effectiveness ratio was $21,600 per QALY gained. TADV demonstrated to be highly cost effective across the range of sensitivity analyses explored, including scenarios considering application of the new technology add-on payment. CONCLUSIONS: TADV with the LimFlow System resulted in significantly improved limb salvage, survival, and AFS rates at 1 year compared with the SoC. Based on projections using a previously validated health economic model, these improvements were shown to translate to meaningful lifetime benefits that help to justify the upfront cost of TADV, rendering it a cost-effective intervention for no-option CLTI patients.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Powell RJ, Dua A, Clair DG, et al. Clinical and economic outcomes of transcatheter arterialization of the deep veins in no-option chronic limb-threatening ischemia patients compared with conventional therapy. J Vasc Surg. 2026. PMID: 41610926. doi:10.1016/j.jvs.2026.01.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。